What are the most valued startups in the healthcare AI market?

Last updated: 9 June 2026

Download our beautiful pitch about the healthcare AI market

market research pitch 2026 statistics healthcare AI market

In our healthcare AI market deck, you will find everything you need to understand the market

The healthcare AI market is now one of the most valuable startup categories in artificial intelligence, with leaders spanning drug discovery, clinical documentation, diagnostics, care operations, and healthcare data infrastructure.

This constantly refreshed ranking tracks the top healthcare AI startups by valuation, using the latest reported, implied, or estimated valuation data available.

We update this list every month so investors, founders, operators, and analysts can follow how value is shifting across the healthcare AI market.

And if you want to better understand this new industry, you can download our pitch covering the healthcare AI market.

A quick summary table

Metric Value
Most valuable healthcare AI startup Isomorphic Labs
Second most valuable healthcare AI startup OpenEvidence
Median healthcare AI valuation About $525M
Share of total healthcare AI valuation captured by the top 10 About 50%
Top healthcare AI startup valuation vs. median About 38x
Median healthcare AI valuation-to-capital-raised ratio About 3.0x
Healthcare AI startups valued at $1B+ 33 startups
Market map chart showing top companies and startups in the healthcare AI market

This market map, featured in our healthcare AI market deck, highlights top companies and startups in the healthcare AI market

Top startups in the healthcare AI market ranked by valuation

Here is an updated table that ranks the top startups in the healthcare AI market based on their latest reported or estimated valuations.

If you want more detaild about their fundraising activity, you can check our list of the startups who have raised the most funding in the healthcare AI market.

# Startup Name What They Do Current Valuation ($) Valuation Confidence Level Valuation Type Evidence Status Total Funding ($) Funding Confidence Level
1 Isomorphic Labs AI drug discovery engine $14.0B–$26.3B Partial Confidence Implied Valuation from Raise Implied $2.7B Full Confidence
2 OpenEvidence Medical evidence AI search $12.0B Full Confidence Announced Private Round Valuation Observed $735M Partial Confidence
3 Tempus AI precision medicine data $8.7B Full Confidence Public Market Cap Observed $1.2B Partial Confidence
4 Commure Healthcare operations AI platform $7.0B Full Confidence Announced Private Round Valuation Observed $570M Partial Confidence
5 Abridge AI clinical documentation $5.0B–$5.6B Strong Confidence Announced Private Round Valuation Observed $758M Strong Confidence
6 XtalPi AI drug discovery robotics $3.9B Full Confidence Public Market Cap Observed $911M Strong Confidence
7 Hippocratic AI Healthcare LLM agents $3.5B Full Confidence Announced Private Round Valuation Observed $404M Strong Confidence
8 Innovaccer Healthcare intelligence cloud $3.2B–$3.7B Partial Confidence Announced Private Round Valuation Observed $547M Partial Confidence
9 Xaira Therapeutics AI drug discovery biotech $2.7B–$4.0B Partial Confidence Announced Private Round Valuation Estimated $1.0B Full Confidence
10 Komodo Health Healthcare data analytics platform $2.8B–$3.5B Strong Confidence Revenue or ARR Multiple Estimate Estimated $514M Strong Confidence
11 Insilico Medicine Generative AI drug discovery $2.6B Full Confidence Public Market Cap Observed $811M Strong Confidence
12 Relay Therapeutics Protein-motion drug discovery $2.5B Full Confidence Public Market Cap Observed $920M Full Confidence
13 Generate:Biomedicines Generative protein therapeutics $1.8B–$3.0B Partial Confidence Implied Valuation from Raise Implied $693M Full Confidence
14 HeartFlow AI coronary artery diagnostics $2.4B Full Confidence Public Market Cap Observed $1.1B Partial Confidence
15 insitro ML-powered drug discovery $1.5B–$2.4B Low Confidence Comparables-Based Estimate Estimated $643M Full Confidence
16 METiS Therapeutics AI drug delivery platform $1.9B Strong Confidence Public Market Cap Observed $576M Partial Confidence
17 Formation Bio AI-native drug development $1.6B–$2.0B Partial Confidence Comparables-Based Estimate Estimated $608M Partial Confidence
18 Medable Decentralized clinical trial software $1.5B–$2.1B Partial Confidence Revenue or ARR Multiple Estimate Estimated $507M Strong Confidence
19 Recursion Pharmaceuticals AI drug discovery platform $1.8B Full Confidence Public Market Cap Observed $1.1B Full Confidence
20 Freenome Early cancer blood testing $1.5B–$2.0B Partial Confidence Announced Private Round Valuation Estimated $1.4B Full Confidence
21 Pathos AI AI oncology drug development $1.5B–$1.7B Strong Confidence Announced Private Round Valuation Observed $467M Partial Confidence
22 AbCellera AI antibody discovery platform $1.6B Full Confidence Public Market Cap Observed $671M Full Confidence
23 Aidoc Clinical imaging AI platform $1.0B–$1.9B Partial Confidence Implied Valuation from Raise Implied $400M Strong Confidence
24 Genesis Therapeutics AI small-molecule drug discovery $1.1B–$1.7B Partial Confidence Implied Valuation from Raise Estimated $280M Strong Confidence
25 Ambience Healthcare Ambient clinical documentation AI $1.2B–$1.4B Strong Confidence Announced Private Round Valuation Observed $343M Strong Confidence
26 Chai Discovery AI molecular design platform $1.3B Full Confidence Announced Private Round Valuation Observed $230M Full Confidence
27 Cohere Health AI prior authorization platform $1.0B–$1.6B Partial Confidence Revenue or ARR Multiple Estimate Estimated $196M Strong Confidence
28 Huma AI digital health platform $1.0B–$1.4B Partial Confidence Revenue or ARR Multiple Estimate Estimated $355M Partial Confidence
29 Valo Health AI-enabled drug development $900M–$1.5B Partial Confidence Comparables-Based Estimate Estimated $400M Partial Confidence
30 Owkin Federated AI drug discovery $800M–$1.2B Low Confidence Comparables-Based Estimate Estimated $304M Strong Confidence
31 Profluent AI protein design $700M–$1.3B Partial Confidence Implied Valuation from Raise Implied $150M Full Confidence
32 Viz.ai AI care coordination imaging $800M–$1.2B Partial Confidence Announced Private Round Valuation Estimated $250M Strong Confidence
33 Cleerly AI cardiac imaging $700M–$1.2B Partial Confidence Implied Valuation from Raise Implied $383M Partial Confidence
34 PathAI AI pathology analysis $750M–$1.05B Strong Confidence Acquisition Value Observed $240M Strong Confidence
35 Immunai AI immune-system mapping $700M–$1.1B Partial Confidence Comparables-Based Estimate Estimated $295M Full Confidence
36 Clarify Health Solutions Value-based care analytics $700M–$1.1B Partial Confidence Revenue or ARR Multiple Estimate Estimated $332M Partial Confidence
37 SmarterDx Clinical revenue integrity AI $700M–$1.1B Partial Confidence Comparables-Based Estimate Estimated $71M Partial Confidence
38 Iterative Health AI clinical research network $650M–$900M Strong Confidence Implied Valuation from Raise Implied $262M Strong Confidence
39 Exo AI handheld ultrasound platform $600M–$900M Partial Confidence Implied Valuation from Raise Implied $420M Partial Confidence
40 CytoReason Computational disease models $550M–$900M Partial Confidence Implied Valuation from Raise Implied $100M Partial Confidence
41 Lunit AI cancer imaging diagnostics $690M Full Confidence Public Market Cap Observed $301M Strong Confidence
42 Exscientia AI drug discovery $636M–$688M Strong Confidence Acquisition Value Observed $839M Strong Confidence
43 Nabla Ambient clinical AI assistant $500M–$800M Strong Confidence Implied Valuation from Raise Implied $120M Strong Confidence
44 Qure.ai AI radiology diagnostics $500M–$800M Partial Confidence Implied Valuation from Raise Implied $121M Strong Confidence
45 Verge Genomics AI neurodegenerative drug discovery $400M–$800M Low Confidence Comparables-Based Estimate Estimated $134M Strong Confidence
46 RapidAI AI stroke imaging workflow $450M–$700M Partial Confidence Implied Valuation from Raise Implied $100M Full Confidence
47 Saama AI clinical data analytics $430M–$700M Partial Confidence Acquisition Value Estimated $505M Partial Confidence
48 Rad AI Generative radiology workflow automation $525M–$600M Strong Confidence Announced Private Round Valuation Observed $147M Strong Confidence
49 Notable Healthcare workflow automation $400M–$700M Partial Confidence Comparables-Based Estimate Estimated $117M Full Confidence
50 BenchSci AI preclinical R&D platform $400M–$650M Partial Confidence Implied Valuation from Raise Estimated $170M Partial Confidence
51 Proscia AI digital pathology platform $400M–$650M Strong Confidence Implied Valuation from Raise Implied $128M Full Confidence
52 Iambic Therapeutics AI-designed therapeutics platform $450M–$580M Strong Confidence Announced Private Round Valuation Observed $334M Partial Confidence
53 Qventus AI care operations automation $400M–$550M Strong Confidence Announced Private Round Valuation Estimated $200M Strong Confidence
54 Corti Healthcare AI co-pilot $350M–$600M Partial Confidence Implied Valuation from Raise Implied $92M Strong Confidence
55 Causaly Biomedical knowledge AI platform $350M–$575M Partial Confidence Implied Valuation from Raise Estimated $93M Strong Confidence
56 Aqemia Physics AI drug discovery $350M–$550M Partial Confidence Implied Valuation from Raise Implied $103M Strong Confidence
57 Nym Autonomous medical coding $300M–$550M Partial Confidence Implied Valuation from Raise Implied $95M Full Confidence
58 Ibex Medical Analytics AI cancer pathology diagnostics $300M–$550M Partial Confidence Implied Valuation from Raise Implied $104M Strong Confidence
59 Suki AI clinical assistant $300M–$500M Partial Confidence Announced Private Round Valuation Estimated $168M Strong Confidence
60 Regard AI clinical insights platform $350M–$450M Partial Confidence Announced Private Round Valuation Observed $81M Partial Confidence
61 Lindus Health AI-enabled clinical trials $290M–$500M Partial Confidence Implied Valuation from Raise Implied $78M Full Confidence
62 Tandem Health AI clinician documentation copilot $300M–$420M Partial Confidence Implied Valuation from Raise Implied $60M Full Confidence
63 Unlearn Clinical trial digital twins $300M–$420M Partial Confidence Implied Valuation from Raise Implied $135M Strong Confidence
64 SOPHiA GENETICS Data-driven medicine analytics $345M Full Confidence Public Market Cap Observed $503M Partial Confidence
65 Ultromics AI echocardiography diagnostics $300M–$380M Partial Confidence Announced Private Round Valuation Estimated $103M Partial Confidence
66 AKASA AI revenue-cycle automation $250M–$400M Low Confidence Proxy-Based Estimate Estimated $85M Full Confidence
67 CodaMetrix Autonomous medical coding $250M–$400M Partial Confidence Announced Private Round Valuation Estimated $111M Strong Confidence
68 Healx AI rare-disease drug discovery $250M–$400M Partial Confidence Revenue or ARR Multiple Estimate Estimated $115M Partial Confidence
69 Aignostics AI pathology precision medicine $225M–$375M Partial Confidence Implied Valuation from Raise Implied $54M Full Confidence
70 AliveCor AI personal ECG devices $200M–$400M Partial Confidence Revenue or ARR Multiple Estimate Estimated $114M Partial Confidence
71 Manas AI AI cancer drug discovery $220M–$340M Partial Confidence Implied Valuation from Raise Implied $51M Full Confidence
72 Eko Health AI heart-lung diagnostics $241M–$271M Strong Confidence Announced Private Round Valuation Estimated $165M Strong Confidence
73 Atomwise AI small-molecule screening $180M–$320M Low Confidence Implied Valuation from Raise Estimated $219M Strong Confidence
74 Turbine Virtual cell simulations $170M–$310M Strong Confidence Implied Valuation from Raise Implied $62M Partial Confidence
75 Tandem AI AI wet-lab drug discovery $180M–$300M Partial Confidence Implied Valuation from Raise Implied $82M Full Confidence
76 Quris-AI AI clinical-prediction platform $150M–$250M Low Confidence Implied Valuation from Raise Implied $37M Strong Confidence
77 Empatica AI medical wearables biomarkers $120M–$250M Low Confidence Implied Valuation from Raise Estimated $33M Strong Confidence
78 Frontera Health AI-enabled autism care $130M–$210M Partial Confidence Implied Valuation from Raise Implied $32M Strong Confidence
79 Caption Health AI-guided ultrasound scanning $150M Full Confidence Acquisition Value Observed $59M Partial Confidence
80 Memora Health Digital care navigation platform $100M–$200M Low Confidence Acquisition Value Estimated $81M Partial Confidence
81 Sift Healthcare AI healthcare payments intelligence $110M–$190M Partial Confidence Implied Valuation from Raise Implied $30M Partial Confidence
82 Zebra Medical Vision AI radiology image analysis $100M–$200M Strong Confidence Acquisition Value Observed $50M Full Confidence
83 ClosedLoop Healthcare predictive AI platform $100M–$180M Low Confidence Comparables-Based Estimate Estimated $45M Strong Confidence
84 Augmedix Ambient medical documentation $139M Full Confidence Acquisition Value Observed $118M Partial Confidence
85 Biofourmis AI remote patient monitoring $80M–$180M Low Confidence Acquisition Value Estimated $461M Strong Confidence
86 Ezra AI full-body MRI screening $90M–$160M Low Confidence Acquisition Value Estimated $43M Strong Confidence
87 Janus AI Revenue cycle automation AI $90M–$150M Low Confidence Implied Valuation from Raise Implied $63M Partial Confidence
88 Iktos Generative AI drug design $70M–$130M Low Confidence Comparables-Based Estimate Estimated $16M Full Confidence
89 DeepScribe Ambient AI medical scribe $60M–$120M Low Confidence Revenue or ARR Multiple Estimate Estimated $60M Partial Confidence
90 Deep 6 AI Clinical trial patient matching $60M–$120M Low Confidence Proxy-Based Estimate Estimated $50M Partial Confidence
91 Paige AI digital pathology diagnostics $81M Full Confidence Acquisition Value Observed $241M Strong Confidence
92 QuantHealth AI clinical trial simulation $60M–$100M Partial Confidence Implied Valuation from Raise Implied $30M Partial Confidence
93 Arterys Cloud AI medical imaging $40M–$90M Low Confidence Acquisition Value Estimated $70M Strong Confidence
94 SigTuple AI diagnostic microscopy automation $40M–$75M Low Confidence Implied Valuation from Raise Implied $33M Strong Confidence
95 BenevolentAI AI drug discovery platform $40M–$50M Partial Confidence Acquisition Value Estimated $734M Partial Confidence
96 Lantern Pharma AI precision oncology therapeutics $42M Full Confidence Public Market Cap Observed $98M Partial Confidence
97 Olive AI Healthcare admin automation AI $0M–$25M Low Confidence Acquisition Value Estimated $856M Partial Confidence
98 OneThree Biotech AI drug discovery platform $8M–$15M Low Confidence Proxy-Based Estimate Estimated $3M Partial Confidence
99 Kheiron Medical Technologies AI breast cancer screening $2M Full Confidence Acquisition Value Observed $22M Partial Confidence
Chart comparing the 2026 size of the healthcare AI market with other markets of similar size

This chart, featured in our healthcare AI market deck, compares the 2026 size of the healthcare AI market with other markets of similar size

Key valuation trends in the healthcare AI market

Insights

  • Healthcare AI value is highly concentrated, with the top 10 startups capturing about half of the total valuation in this ranking.
  • Clinical documentation and healthcare AI assistants have become a premium investment theme, led by Abridge, Hippocratic AI, Ambience Healthcare, and Nabla.
  • Drug discovery remains the largest value pool in healthcare AI, but the category is also capital intensive, with several leaders raising hundreds of millions or more.
  • Public healthcare AI companies anchor a meaningful part of the market, especially across precision medicine, drug discovery, diagnostics, and antibody discovery.
  • Strategic exits have produced mixed outcomes in healthcare AI, with some acquisitions landing below total funding while focused pathology and imaging assets still attract buyers.
  • Chai Discovery and Hippocratic AI stand out as unusually capital efficient healthcare AI companies, with high valuations relative to total funding raised.
  • Healthcare workflow AI is spreading beyond clinical notes into coding, revenue integrity, care operations, prior authorization, and patient navigation.
  • Imaging and diagnostics startups are numerous, but the category is less top-heavy than drug discovery or clinical workflow AI.
Chart showing Tempus AI’s strategy in the healthcare AI market

This chart, featured in our healthcare AI market deck, looks at Tempus AI’s strategy in healthcare AI

A few word about our methodology

As you can see, we built a database that ranks startups in the healthcare AI market based on their current valuation.

Estimating healthcare AI startup valuations is not always straightforward. Many companies do not publicly disclose their valuation, and the available information can vary widely depending on the company, its stage, and its business model.

To build this ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.

Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed companies, or official acquisition prices.

When a healthcare AI company is publicly listed, we use its current market capitalization as the reference valuation.

If a healthcare AI startup was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.

When a startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.

In some cases, we also estimate valuations using operating metrics such as revenue, ARR, customer traction, clinical adoption, enterprise contracts, or product usage, combined with valuation multiples from comparable healthcare AI companies.

When direct financial data is not available, we may rely on carefully selected comparable startups and other signals such as hiring growth, investor quality, product traction, clinical validation, regulatory progress, or partnership activity.

All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by public market data, acquisition values, strong operating metrics, and comparable company analysis.

We also carefully evaluate the age of every data point. Recent information carries more weight, while older data is treated cautiously and adjusted conservatively when necessary.

Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.

Because healthcare AI valuation data is not always fully public, each startup in the ranking is assigned a confidence level based on the reliability, recency, and consistency of the available evidence.

Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.

When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.

This reflects how we conduct all our research, including the work behind our report covering the healthcare AI market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

Chart showing the projected CAGR of the healthcare AI market

This chart, featured in our healthcare AI market deck, shows annual funding in healthcare AI startups

Related blog posts

- What is the latest news in healthcare AI?

- What is the latest funding news in healthcare AI?

- What is the latest update in healthcare AI?

- How funding activity has changed in healthcare AI

- What are the latest fundraising trends in healthcare AI?

- What is the real size of the healthcare AI market?

- A complete list of business models in the healthcare AI market

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog